Epithelial Ovarian Cancer Market Report 2025

This Epithelial Ovarian Cancer market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The epithelial ovarian cancer market size has grown rapidly in recent years. It will grow from $2.08 billion in 2024 to $2.42 billion in 2025 at a compound annual growth rate (CAGR) of 16.5%. The growth during the historical period can be attributed to factors such as the increasing demand for personalized cancer treatments, rising global healthcare spending, a growing preference for minimally invasive surgeries, a higher number of ovarian cancer survivors, increased demand for gene therapies, and a rise in the need for palliative care services.

The epithelial ovarian cancer market size is expected to see rapid growth in the next few years. It will grow to $4.41 billion in 2029 at a compound annual growth rate (CAGR) of 16.1%. In the forecast period, growth is expected due to the increasing incidence of ovarian cancer, an aging population, greater awareness of ovarian cancer, more research funding for cancer, and growing government initiatives aimed at combating cancer. Key trends during this period include technological advancements in medical imaging, the introduction of new molecular diagnostic tools, collaborations between pharmaceutical companies, the rapid adoption of AI and machine learning in diagnostics, and a growing use of robotic surgeries.

The growing incidence of ovarian cancer is expected to drive the expansion of the epithelial ovarian cancer market in the coming years. Ovarian cancer begins in the ovaries, primarily affecting the epithelial cells that line their surface. This increase in prevalence is largely attributed to an aging population, better awareness, improved detection rates, and factors such as genetics and lifestyle. Treatment for epithelial ovarian cancer is essential in addressing this common and aggressive form of the disease, targeting malignant cells to enhance survival and patient outcomes. According to the World Ovarian Cancer Coalition, a non-profit organization based in Canada, the global number of women diagnosed with ovarian cancer is projected to rise by over 55% by 2050, reaching 503,448. Additionally, annual deaths from ovarian cancer are expected to increase by nearly 70% from 2022, reaching 350,956. As a result, the growing prevalence of ovarian cancer will propel the market for epithelial ovarian cancer treatments.

Leading companies in the epithelial ovarian cancer market are focusing on developing cutting-edge treatment solutions, such as FRα-directed antibody-drug conjugates (ADCs), which target the folate receptor-alpha overexpressed on cancer cells. These treatments deliver potent cytotoxic agents directly to the cancer cells, while minimizing damage to healthy tissues. For example, in November 2024, AbbVie Inc., a biopharmaceutical company based in the United States, received European Commission approval for ELAHERE (mirvetuximab soravtansine). This targeted therapy is designed for adult patients with FRα-positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. ELAHERE offers an effective treatment option for patients who have undergone up to three prior systemic regimens. By targeting a biomarker present in about one-third of ovarian cancer patients, it improves survival prospects and enhances the patient's quality of life. The approval also includes a companion diagnostic to help identify eligible patients.

In February 2024, AbbVie Inc. acquired ImmunoGen in a deal worth $10.1 billion to expand its oncology portfolio. This acquisition brings ELAHERE, a targeted antibody-drug conjugate for treating platinum-resistant ovarian cancer, into AbbVie’s offerings. The move aims to reduce reliance on older drugs and position AbbVie within the growing ADC market. ImmunoGen, a US-based manufacturer, specializes in drugs for epithelial ovarian cancer.

Major players in the epithelial ovarian cancer market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck KGaA, Siemens Healthineers AG, Quest Diagnostics Incorporated, Eisai Co. Ltd., Genentech Inc., Qiagen N.V., Myriad Genetics Inc., Zymeworks Inc., Novogen Limited, Karyopharm Therapeutics Inc., Clovis Oncology Inc., ImmunoGen Inc., Fujirebio Diagnostics Inc., and Vivesto AB.

North America was the largest region in the epithelial ovarian cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in epithelial ovarian cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the epithelial ovarian cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Epithelial ovarian cancer (EOC) is the most common form of ovarian cancer, originating from the epithelial cells that make up the outer layer of the ovary. It typically affects women over the age of fifty and is often asymptomatic in the early stages, resulting in late-stage diagnoses when the cancer has already progressed. When symptoms do appear, they may include abdominal bloating, pelvic pain, frequent urination, and changes in bowel movements.

The main treatment options for epithelial ovarian cancer include chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and surgery. Chemotherapy involves the use of drugs to kill or slow the growth of cancer cells, with options such as platinum-based drugs, poly(adp-ribose) polymerase inhibitors, bevacizumab, and other chemotherapeutic agents. Chemotherapy is used in both early and advanced stages of the disease. Diagnosis can be made through imaging, biopsies, and blood tests, and the treatment is commonly administered in hospitals, clinics, and diagnostic laboratories.

The epithelial ovarian cancer market research report is one of a series of new reports that provides epithelial ovarian cancer market statistics, including epithelial ovarian cancer industry global market size, regional shares, competitors with a epithelial ovarian cancer market share, detailed epithelial ovarian cancer market segments, market trends and opportunities, and any further data you may need to thrive in the epithelial ovarian cancer industry. This epithelial ovarian cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The epithelial ovarian cancer market consists of revenues earned by entities by providing services such as genetic testing, supportive care services, telemedicine, and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The epithelial ovarian cancer market also includes sales of diagnostic kits, targeted therapy drugs, chemotherapeutic agents, surgical instruments, and devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.